Publikationen

Aktuelle Veröffentlichungen (Auswahl)

Alavi-Demirci, S., Beckmann, L. N., Woopen, H., Liebrich, C., Virk, Y., Wimberger, P., Kubiak, K., Ligl-Löhner, A., Enzinger, H.-M., Czolk, V., Kunz, G., Mangler, M., Lantzsch, T., Mustea, A., Fechner, S., Burdack, A., Terhaag, J., Fischer, D., Müller, C., & Sehouli, J. (2026). Expression VIII: Final Results of the Individual Perception and Level of Information of Patients with Borderline Tumors of the Ovary. Current Oncology, 33(9), 516. doi:10.3390/curroncol33090516

Dimitrova, D., Boer, J. D., Zocholl, D., Krajewska, M., Woopen, H., Nasser, S., Pirmorady-Sehouli, A., Jansen, H., Kiechle, M., & Sehouli, J. (2026). Patients’ Perspectives on Changes in Cancer Care During the COVID-19 Pandemic: Results of a Survey Among Patients with Gynecological Malignancies and Breast Cancer in Germany (NOGGO-S25/Expression XIII). Current Oncology, 33(8), 484. doi:10.3390/curroncol33080484

Dimitrova, D., Samartzis, E. P., Zocholl, D., Barretina-Ginesta, M.-P., Leitner, K., Havelka, P., Achimas-Cadariu, P., Taskiran, C., Mittelstadt, S., Van Nieuwenhuysen, E., Bauerschmitz, G., Heinzelmann-Schwarz, V., Madariaga, A., Ringsdorf, U., Zwimpfer, T., Madroñal, C., Enzinger, H.-M., Al Rubaish, S., Sehouli, J., & Woopen, H. (2026). Long-Term Young Adult Cancer Survivors with Ovarian Cancer: Subgroup Analysis of the Study “Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer”: The International NOGGO, ENGOT, and GCIG Survey. Cancers, 18(7), 1183. doi:10.3390/cancers18071183

Steinkasserer L, Wilhelm LM, Schambach J, Schäffler H, Tahmasbi Rad M, Schochter F, Bokhua D, Huber Z, Hillemanns P, Hertel H, Flethe C, Pietzner K and Sehouli J (2026). Analysis of the temporal changes in management of early-stage cervical cancer over a 10-year period in Germany: a multicenter retrospective analysis of the JAGO/NOGGO. Front. Oncol. 16:1916573. doi: 10.3389/fonc.2026.1916573

Woopen, H., Zwimpfer, T., Brenner, L., Liebrich, C., Leitner, K., Henry, S., Müller, C., Saner, F. A. M., Ebner, C., Dimitrova, D., Mang, C., Himsl, I., Hell-Teutsch, J., Van Gorp, T., Braun, C., Nurhayat, Y., Müller, M., Hanker, L., Heinzelmann-Schwarz, V., & Sehouli, J. (2026). Patients’ Perception of Follow-Up Care and Personal Health Status of 677 Long-Term Survivors of Gynecological Cancer from the Study “Expression IX—Long-Term Survival with Gynecological Cancer”: The International NOGGO, ENGOT and GCIG Survey. Cancers, 18(10), 1647. doi: 10.3390/cancers18101647

Sehouli J, Pietzner K, Zocholl D, Nguyen J, Leitner K, Eichbaum M, Goldmann J, Frühauf F, Van Gorp T, Estévez-García P, Katsaros D, Braicu EI. A randomized, open-label phase II non-inferiority study of niraparib maintenance after 3 versus 6 cycles of platinum-based chemotherapy in patients with completely debulked advanced HRD-positive high-grade ovarian cancer in first-line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62). Int J Gynecol Cancer. 2026 May 15:104557. doi: 10.1016/j.ijgc.2026.104557.

Proppe L, Zimmermann JSM, Hachenberg J, Pan T, Tsibulak I, Radosa JC, Botscharnikow C, Flethe C, Sehouli J, Pietzner K. Women with first recurrence of endometrial cancer: who are they? An analysis of real-world data of the JAGO/NOGGO. BMC Cancer. 2025 Dec 2;25(1):1849. doi: 10.1186/s12885-025-15168-8.

Barretina-Ginesta MP, Madariaga A, Gil-Martin M, Ramchandani A, Pardo M, Sanchez-Heras AB, Churrucaga C, Guerra-Alia EM, Madroñal C, Fernandez-Plana J, Herrero A, Dotor E, Esteban C, Quindós-Varela M, Romeo M, Gost E, Bermejo MJ, Fernandez-Chacón C, Ferrer N, Gomez-Raposo C, Catot Tort S, Eichbaum M, Sehouli J, Woopen H. Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohort. International Journal of Gynecological Cancer, Volume 0, Issue 0, 102758. doi:10.1016/j.ijgc.2025.102758.

Sehouli J, Forrest MR, Boer JD, Grabowski JP, Coleman RL, Fechner S, Bogani G, Ecker T, Fischer E, Fotopoulou C, Ito C, Krannich A, Krull A, Madariaga A, Monk BJ, Oskay-Öczelik G, Rose M, Sinn F, Wimberger P, Kurth T. Comparing nab-paclitaxel and solvent-based paclitaxel in platinum-resistant ovarian cancer: evidence and perspectives. Int J Gynecol Cancer. 2025 Dec 11:102841. doi: 10.1016/j.ijgc.2025.102841. 

Grabowski JP, Welz J, Heublein S, Krajewska M, Boer JD, Kraus F, Arndt T, Moosmann N, Heinrich B, Engler T, Agabejli S, Ugur MC, Witteler R, Albrecht O, Müller-Huesmann H, Oskay-Özcelik G, Hettwer C, Kaiser S, Braicu E, Sehouli J. Between research and introduction to clinical routine-Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis). Arch Gynecol Obstet. 2026 Jan 6;313(1):11. doi: 10.1007/s00404-025-08295-x

Balint N, Woopen H, Richter R, Pirmorady-Sehouli A, Pietzner K, Sehouli J. Sexuality as a Prognostic Factor—Results of an Individual Patient Data NOGGO (North-Eastern German Society of Gynecological Oncology)-Meta-Analysis of 644 Recurrent Ovarian Cancer Patients Prior to Chemotherapy.Cancers (Basel). 2024;16(4):811. doi: 10.3390/cancers16040811.

Beck MH, Balci-Hakimeh D, Scheuerecker F, Wallach C, Güngor HL, Lee M, Abdel-Kawi AF, Glajzer J, Vasiljeva J, Kubiak K, Blohmer JU, Sehouli J, Pietzner K. Real-World Evidence: How Long Do Our Patients Fast?-Results from a Prospective JAGO-NOGGO-Multicenter Analysis on Perioperative Fasting in 924 Patients with Malignant and Benign Gynecological Diseases. Cancers (Basel). 2023;15(4):1311. doi: 10.3390/cancers15041311.

Biersack MG, Volmer LL, Geißler C, Fromme J, Fröhlich S, Pietzner K, Sehouli J, Beck MH. Informed consent in gynecological oncology: a JAGO/NOGGO survey on real-world practices in daily clinical routine. Arch Gynecol Obstet. 2025 Feb;311(2):451-457. doi: 10.1007/s00404-024-07776-9.

Chinczewski L, Harter P, Heukamp L, Mayr D, Grimm C, Heinzelmann-Schwarz V, Wimberger P, Mahner S, Braicu IE, Schmitt W, Denkert C, Sehouli J. Intergroup-statement: statement of the german ovarian cancer commission, the North-Eastern German Society of gynecological Oncology (NOGGO), AGO Austria and AGO Swiss regarding the use of homologous repair deficiency (HRD) assays in advanced ovarian cancer.Arch Gynecol Obstet. 2025 May;311(5):1445-1450. doi: 10.1007/s00404-025-07991-y.

Dimitrova D, Boer J, Karaman M, Bookman M, Brand A, O'Donnell J, Oza A, Pothuri B, Bennett K, Sehouli J. Perspectives on inclusion, diversity, equity, and access in clinical trials: findings from a six-continent survey. Int J Gynecol Cancer. 2025;101625. doi: 10.1016/j.ijgc.2024.101625.

Herzog EM, Pirmorady Sehouli A, Boer J, Pietzner K, Petru E, Heinzelmann V, Roser E, Dimitrova D, Oskay-Özcelik G, Camara O, Sehouli J. How to break bad news and how to learn this skill: results from an international North-Eastern German Society for Gynecological Oncology (NOGGO) survey among physicians and medical students with 1089 participants. Int J Gynecol Cancer. 2023;33(12):1934-1942. doi: 10.1136/ijgc-2023-004693.

Inci MG, Ilter E, Roser E, Dimitrova D, Kofiah R, Stoklossa C, Karaman M, Goerling U, Plett H, Aktas B, Mangler M, Lanowska M, Oskay-Oeczelik G, Barinoff J, Wimberger P, Pirmorady-Sehouli A, Schmalfeldt B, Mayr D, Letsch A, Maass N, Harter P, Mahner S, Hanf V, Hasenburg A, Sehouli J. Experiences and expectations of advance directives in gynecological cancer patients (The NOGGO-Expression X Study).Int J Gynecol Cancer. 2025;102008. doi:10.1016/j.ijgc.2025.102008.

Lindemann K, Berton D, Sehouli J, Christensen RD, Altintas S, Knudsen AØ, Heudel PE, Ataseven B, Vergote I, Lindahl G, Lebreton C, Schochter F, Auranen A, Follana P, Madsen K, Selle F, Petersson KS, Joly F, Braicu EI, Mirza MR. NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer. Gynecol Oncol. 2025 Jun 30;199:79-87. doi: 10.1016/j.ygyno.2025.06.008.

Mirza MR, Bjørge L, Marmé F, Christensen RD, Gil-Martin M, Auranen A, Ataseven B, Rubio MJ, Salutari V, Luczak AA, Runnebaum IB, Redondo A, Lindemann K, Trillsch F, Ginesta MPB, Roed H, Kurtz JE, Petersson KS, Nyvang GB, Sehouli J. Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial. Gynecol Oncol. 2025 Jan;192:128-136. doi: 10.1016/j.ygyno.2024.12.003.

Pfarr N, von Schwarzenberg K, Zocholl D, Merkelbach-Bruse S, Siemanowski J, Mayr EM, Herold S, Kleo K, Heukamp LC, Willing EM, Menzel M, Lehmann U, Bartels S, Chakraborty S, Baretton G, Demes MC, Döring C, Kazdal D, Budczies J, Rad R, Wild P, Christinat Y, McKee T, Schirmacher P, Horst D, Büttner R, Stenzinger A, Sehouli J, Vollbrecht C, Hummel M, Braicu EI, Weichert W. German HRD assay Harmonization Consortium. High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer. JCO Precis Oncol. 2024;e2300348. doi: 10.1200/PO.23.00348.

Riedel M, Herrmann H, Bartl T, Rossner AM, Tatzber A, Flethe C, Zocholl D, Schmalfeldt B, Sehouli J, Pietzner K. The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey. BMC Cancer. 2025 Jan 29;25(1):170. doi: 10.1186/s12885-025-13432-5.

letzte Aktualisierung: 29.07.2025